| Outcome Measures: |
Primary: severity and duration for all adverse events, Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose, 30 days after last dose|Abnormal laboratory findings, Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose, 30 days after last dose|Abnormal physical findings, Incidence, severity, and duration for all adverse events (AEs), and abnormal laboratory and physical findings up until 30 days after last dose, 30 days after last dose | Secondary: Change ALT levels, Day 30 versus Day 1 serum ALT levels, Day 30 versus Day 1 serum ALT levels|Change in HbA1c levels, HbA1c levels, Day 30 versus Day 1|change in HOMA/HOMA-IR scores, Day 30 versus Day 1 change in HOMA/HOMA-IR scores. Insulin and fasting plasma glucose will be measured to calculate HOMA/HOMA-IR, Day 30 versus Day 1 | Other: Body mass index (BMI), Measurment of BMI (kg/m\^2) Serum lipid profile: total cholesterol, triglycerides, low density lipoprotein (LDL) and high density lipoprotein (HDL) fractions., Day 1 versus day 30 and 60|Change in Immunological markers, C-reactive protein (CRP) b. T cell-associated cytokine levels (IL2, 4, 5, 6, 8,10,12, 13, IFN, TNF, TGF c. Regulatory T cell (Tregs) levels (cells positive for: CD4, CD25, CD8, CD56, CD3, CD62, CD127, NKT, FoxP3, LAP), Day 1 versus day 30 and 60|Cytokine levels, Measurement of Cytokine levels Mean serum concentrations of, cytokeratin (CK)-18 fragments, C-peptide, glucagon-like peptide-1 (GLP-1), adiponectin c. 13C-Methacetin breath test (MBT) Hepatic steatosis and fibrosis, Day 1 versus day 30 and 60|waist circumference, measurement of waist circumference (cm), Day 1 versus day 30 and 60|Serum lipid profile, Serum lipid concentration will be measured, Day 1 versus day 30 and 60|Regulatory T cell, Measurement of Regulatory T cell, Day 1 versus day 30 and 60|Liver enzymes, Measurement of Liver enzymes, Day 1 versus day 30 and 60|Mean serum concentrations of cytokeratin (CK)-18 fragments, Measurement of (CK)-18 fragments concentration, Day 1 versus day 30 and 60|Mean serum concentrations of C-peptide, Measurement of C-peptide concentration, Day 1 versus day 30 and 60|Mean serum concentrations of glucagon-like peptide-1 (GLP-1), Measurement of glucagon-like peptide-1 (GLP-1) concentration, Day 1 versus day 30 and 60|Mean serum concentrations of adiponectin, Measurement of adiponectin concentration, Day 1 versus day 30 and 60
|
